Christine Marie Utter Sells 1,291 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,291 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $58,533.94. Following the completion of the transaction, the chief accounting officer now directly owns 65,983 shares of the company’s stock, valued at $2,991,669.22. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Monday, December 2nd, Christine Marie Utter sold 17,800 shares of PTC Therapeutics stock. The stock was sold at an average price of $51.77, for a total transaction of $921,506.00.

PTC Therapeutics Stock Down 2.4 %

PTCT stock opened at $43.94 on Friday. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of -7.40 and a beta of 0.62. The company’s fifty day simple moving average is $45.19 and its 200 day simple moving average is $38.47. PTC Therapeutics, Inc. has a 12-month low of $23.58 and a 12-month high of $54.16.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PTCT shares. The Goldman Sachs Group upped their price target on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. StockNews.com cut PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. UBS Group lifted their price target on PTC Therapeutics from $47.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Robert W. Baird upped their price objective on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Finally, Royal Bank of Canada upgraded shares of PTC Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $39.00 to $63.00 in a research report on Tuesday, December 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, PTC Therapeutics has a consensus rating of “Hold” and a consensus target price of $54.08.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV grew its stake in PTC Therapeutics by 29.2% during the third quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 504 shares during the period. CWM LLC boosted its holdings in shares of PTC Therapeutics by 354.7% during the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 2,096 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of PTC Therapeutics by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 492 shares during the period. Quest Partners LLC bought a new stake in shares of PTC Therapeutics in the 2nd quarter valued at $128,000. Finally, Quarry LP lifted its position in shares of PTC Therapeutics by 100.0% during the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,500 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.